PMID- 16176811
OWN - NLM
STAT- MEDLINE
DCOM- 20060613
LR  - 20151119
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 365
IP  - 1-2
DP  - 2006 Mar
TI  - Effects of repeated infliximab therapy on serum lipid profile in patients with 
      refractory rheumatoid arthritis.
PG  - 143-8
AB  - BACKGROUND: Patients with rheumatoid arthritis (RA) frequently display an 
      atherogenic lipid profile which has been linked with inflammation. Tumor necrosis 
      factor-alpha (TNF-alpha), a pivotal pro-inflammatory cytokine in RA may be 
      involved in the development of the disturbed lipid metabolism. We investigated 
      whether infliximab, an anti-TNF-alpha therapy, may modify the lipid profile. 
      METHODS: 56 consecutive RA patients were treated with infliximab (3 mg/kg at 
      weeks 0, 2, 6, 14, 22, 30). Lipid profile and CRP were assayed at baseline and 
      before infusion at weeks 6 and 30. Baseline values were compared with those in 56 
      healthy volunteers. RESULTS: At baseline, the concentrations of HDL-cholesterol 
      were lower in RA patients than in the controls (1.3+/-0.4 vs. 1.5+/-0.2 mmol/L; 
      p<0.01). The triglyceride concentrations (1.6+/-0.8 vs. 1.3+/-0.4 mmol/L, 
      p<0.01), the ratio of total cholesterol/HDL-cholesterol (4.3+/-1.6 vs. 3.2+/-0.5, 
      p<0.001) and LDL-cholesterol/HDL-cholesterol (2.6+/-1.2 vs. 1.7+/-0.5, p<0.001) 
      were significantly higher in RA patients than in controls. After 6 weeks of 
      infliximab therapy, the mean total cholesterol concentration increased by 25% 
      (p<0.001), LDL-cholesterol by 24% (p<0.001) and HDL-cholesterol by 30% (p<0.001). 
      The decrease in CRP levels to 30 week inversely correlated with the increase in 
      HDL-cholesterol (r=-0.47, p=0.005). CONCLUSIONS: Infliximab administration is 
      associated with important increases in cholesterol levels in all its forms but as 
      no significant beneficial effect on the atherogenic ratio.
FAU - Allanore, Yannick
AU  - Allanore Y
AD  - Department of Rheumatology A, Assistance Publique-Hopitaux de Paris, Cochin 
      Hospital, Paris 5 University, 75679 Paris Cedex 14, France.
FAU - Kahan, Andre
AU  - Kahan A
FAU - Sellam, Jeremie
AU  - Sellam J
FAU - Ekindjian, Ohvanesse G
AU  - Ekindjian OG
FAU - Borderie, Didier
AU  - Borderie D
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20050919
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Lipids)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Arthritis, Rheumatoid/*blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Infliximab
MH  - Lipids/*blood
MH  - Male
MH  - Middle Aged
EDAT- 2005/09/24 09:00
MHDA- 2006/06/14 09:00
CRDT- 2005/09/24 09:00
PHST- 2005/07/12 00:00 [received]
PHST- 2005/08/11 00:00 [revised]
PHST- 2005/08/11 00:00 [accepted]
PHST- 2005/09/24 09:00 [pubmed]
PHST- 2006/06/14 09:00 [medline]
PHST- 2005/09/24 09:00 [entrez]
AID - S0009-8981(05)00508-5 [pii]
AID - 10.1016/j.cca.2005.08.010 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2006 Mar;365(1-2):143-8. doi: 10.1016/j.cca.2005.08.010. Epub 
      2005 Sep 19.